Navigation Links
Genomic analysis of prostate cancer indicates best course of action after surgery
Date:7/29/2014

(PHILADELPHIA) There is controversy over how best to treat patients after they've undergone surgery for prostate cancer. Does one wait until the cancer comes back or provide men with additional radiation therapy to prevent cancer recurrence? Now, a new study from Thomas Jefferson University shows that a genomic tool can help doctors and patients make a more informed decision.

"We are moving away from treating everyone the same," says first author Robert Den, M.D., Assistant Professor of Radiation Oncology and Cancer Biology at Thomas Jefferson University. "Genomic tools are letting us gauge which cancers are more aggressive and should be treated earlier with radiation, and which ones are unlikely to benefit from additional therapy."

Although surgery for prostate cancer is meant to be curative, in some men, the cancer can regrow. Doctors have developed high risk criteria based on clinical factors, but these criteria are imperfect predictors of cancer returning, or recurrence. Only about 50 percent of high risk patients ever go on to develop metastases, raising the question of whether those who receive additional therapy are being overtreated.

In an attempt to better understand how to treat their patient population, researchers led by Drs. Den and Adam Dicker, M.D., Ph.D., Chairman of the Department of Radiation Oncology at Jefferson, together with other members of the Kimmel Cancer Center Genitourinary team including Dr. Leonard Gomella, Chairman of the Department of Urology, assessed whether a genomic test designed to predict prostate cancer metastasis could also predict which patients would most benefit from radiation treatment after surgery.

The test, called Decipher, from the genome diagnostics company GenomeDx, generates a gene signature from a patient's cancer tissue sample. Based on this signature, the test stratifies patients into high, intermediate and low risk for cancer recurrence and metastases.

The researchers tested the genomes from tumor samples of 139 patients who had received radiation therapy following prostate surgery at Jefferson. Using medical records, the researchers grouped the patients by the treatments they received after surgery, and matched their records to the results of the genomic analysis.

The genomic analysis correctly predicted outcomes. The patients with a high Decipher score were more likely to develop metastases than those with a low score. In addition, those with a high Decipher score who received radiation earlier had longer survival than those who did not receive radiation immediately after surgery. The results showed that patients treated with radiation after surgery maintained low PSA levels for twice as long than those who were not treated with radiation.

"Our analysis suggests that genomic analysis scores could be used, in concert with other diagnostic measures such as PSA testing, to help determine which patients would benefit from additional radiation therapy and more aggressive measures, and which are less likely to benefit," says Dr. Den.


'/>"/>

Contact: Edyta Zielinska
edyta.zielinska@jefferson.edu
215-955-5291
Thomas Jefferson University
Source:Eurekalert

Related medicine news :

1. Following the genomic pathways to stop the spread of cancer
2. Genomic study of rare childrens cancer yields possible prognostic tool
3. Mayo, UCSF team discovers genomic variant that increases risk of brain tumors
4. Study identifies genes associated with genomic expansions that cause disease
5. $8.9 million NIH grant to study genomic link to premature heart disease
6. Edith Sanford Breast Cancer Foundation and TSRI partner in genomic breast cancer research
7. Molecular Genetics & Genomic Medicine: New open access journal launched by Wiley
8. Ontario Genomics Institute invests in stem cell technology at Tissue Regenerative Therapeutics
9. Study shows large-scale genomic testing feasible, impacts therapy
10. Stanford/Yale study gives insight into subtle genomic differences among our own cells
11. NIH grant moves pathologists to the forefront of genomic medicine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/22/2017)... ... February 22, 2017 , ... In today’s world, homeowners face ... the market, it is easy to start feeling frustrated and confused. To help ... complimentary security consultation. , Home Security Hardware Choices, There are innumerable choices for ...
(Date:2/21/2017)... ... February 22, 2017 , ... Author Michèle Wolff has ... for every household and family to know all about it for optimal health. Wanting ... the release of “ Detox, Digestive and Wellness Solutions ” (published by Balboa Press ...
(Date:2/21/2017)... ... February 21, 2017 , ... As recently as 2015, rhinoplasty was one of ... of Plastic Surgeons. Some patients want to make a change in the appearance of ... their breathing ability. The team at usrhinoplasty.org is expanding its article database ...
(Date:2/21/2017)... ... February 21, 2017 , ... ... the further expansion of its eHealth App xChange™, providing clinical researchers more ... Bioclinica’s extensive and growing eHealth platform. Applications that enable patient-centered clinical trials ...
(Date:2/21/2017)... ... February 21, 2017 , ... A February 6 article on Healio ... It found that the treatments have led to significant improvements in weight loss and ... efforts. It also noted very few problematic results relating to the treatment. Beverly Hills ...
Breaking Medicine News(10 mins):
(Date:2/21/2017)... Feb. 21, 2017 Sangamo Therapeutics, Inc. (Nasdaq: ... that the company will release its fourth quarter and ... on Tuesday, February 28, 2017. The press release will ... ET, which will be open to the public via ... will review its financial results and provide a business ...
(Date:2/21/2017)... Feb. 21, 2017 ... a new imaging solution that connects Lexmark multifunction printers ... of the world,s leading scanning and indexing software solutions ... enables hospitals to use a Lexmark MFP at the ... Solarity workflow, helping facilities reach HIMSS Stage 7 ...
(Date:2/21/2017)... , Feb. 21, 2017 EMS ... mobile and web based platforms with focus on ... announce the signing of a worldwide, on-revocable and ... a full-service medical transportation company serving healthcare organizations ... . EpicMD,s platform eliminates ...
Breaking Medicine Technology: